The ability of MTC to activate cellular defence mechanisms by activation of NRF2 has been revealed in vitro [106] and in ageing, and it is associated with the restoration of deficient antioxidant defence proteins such as NRF1 and SOD2 [51]. This evidence concerns the gene NRF1 and medullary thyroid gland carcinoma.